L, A., R, B., C, K., B, A., P, D., T, A., . . . JP, S. (2024). Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: Insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. Journal for immunotherapy of cancer, 12(8), . https://doi.org/10.1136/jitc-2024-009728
Chicago Style (17th ed.) CitationL, Assoumou, et al. "Safety and Tolerability of Immune Checkpoint Inhibitors in People with HIV Infection and Cancer: Insights from the National Prospective Real-world OncoVIHAC ANRS CO24 Cohort Study." Journal for Immunotherapy of Cancer 12, no. 8 (2024). https://doi.org/10.1136/jitc-2024-009728.
MLA (9th ed.) CitationL, Assoumou, et al. "Safety and Tolerability of Immune Checkpoint Inhibitors in People with HIV Infection and Cancer: Insights from the National Prospective Real-world OncoVIHAC ANRS CO24 Cohort Study." Journal for Immunotherapy of Cancer, vol. 12, no. 8, 2024, https://doi.org/10.1136/jitc-2024-009728.
